FBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-27), Fortress Biotech's share price is $1.72. Fortress Biotech's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-16.36. Hence, Fortress Biotech's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Fortress Biotech's Price-to-Free-Cash-Flow or its related term are showing as below:
Fortress Biotech's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-3.25. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-16.36.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 3.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 9.60% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -8.00% per year.
During the past 13 years, Fortress Biotech's highest 3-Year average Free Cash Flow per Share Growth Rate was 38.50% per year. The lowest was -65.80% per year. And the median was -0.50% per year.
The historical data trend for Fortress Biotech's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortress Biotech Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
Fortress Biotech Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Fortress Biotech's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Fortress Biotech's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Fortress Biotech's Price-to-Free-Cash-Flow falls into.
Fortress Biotech's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 1.72 | / | -16.361 | |
= | N/A |
Fortress Biotech's Share Price of today is $1.72.
Fortress Biotech's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.36.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
Fortress Biotech (NAS:FBIO) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of Fortress Biotech's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Rosenwald Lindsay A Md | director, 10 percent owner, officer: PRESIDENT, CEO & CHAIRMAN | 375 PARK AVE, NEW YORK NY 10152 |
Lucy Lu | director | THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137 |
David Jin | officer: Chief Financial Officer | C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036 |
Dov Klein | director | C/O FORTRESS BIOTECH, INC., 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019 |
Robyn Hunter | officer: Chief Financial Officer | 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453 |
Eric K Rowinsky | director | IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014 |
Malcolm Hoenlein | director | 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
Michael S Weiss | director, 10 percent owner, officer: EXECUTIVE VICE CHAIRMAN | 750 LEXINGTON AVE, NEW YORK NY 10022 |
J Jay Lobell | director | 365 W END AVE, APARTMENT 10A, NEW YORK NY 10024 |
Jimmie Harvey | director | 3741 EAST FAIRWAY DRIVE, BIRMINGHAM AL 35213 |
Kevin Lorenz | director | C/O NUVEEN, 333 W. WACKER DR., CHICAGO IL 60606 |
George Avgerinos | officer: SVP, Biologics Operations | C/O CORONADO BIOSCIENCES, INC., 24 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
Kevin Horgan | other: Former Chief Medical Officer | C/O SOLIGENIX, INC., 29 EMMONS DRIVE, STE. C-10, PRINCETON NJ 08540 |
David Jonathan Barrett | director | ONE PENN PLAZA, SUITE 2514, NEW YORK NY 10119 |
Harlan F Weisman | director | C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
From GuruFocus
By Marketwired • 10-16-2023
By Value_Insider Value_Insider • 12-19-2022
By Marketwired • 08-14-2023
By GuruFocus Research GuruFocus Editor • 10-24-2022
By GuruFocus Research • 01-09-2024
By sperokesalga sperokesalga • 02-16-2023
By Value_Insider Value_Insider • 12-06-2022
By PRNewswire • 12-04-2023
By Marketwired • 09-07-2023
By sperokesalga sperokesalga • 06-15-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.